Tevimbra (tislelizumab-jsgr)

OS subgroup analysis showed comparable treatment effect by TAP score at 10% cutoff, CPS at cutoff 10, and TC score at 1% cutoff. TAP score and CPS at these cutoffs exhibited substantial concordance. Results indicate that the quicker, visually estimated TAP score and CPS may be interchangeable for clinical measurement of PD-L1 expression in patients with ESCC.

In the treatment of locally advanced NPC, a randomized phase III study showed equivalence of induction (ICT) and adjuvant therapy (AT; NCT03306121). PD-1 inhibitors have become established in the palliative therapy of NPC in recent years and could now also play an increasing role in curation: the phase III study "Dipper" showed a significantly better 3‑year event-free survival in patients adjuvantly treated with camrelizumab versus placebo after IT and definitive platinum-containing chemoradiotherapy (dRCT; 89% vs. 80%; NCT03427827). The phase III study "Beacon" showed complete remission in 30.5% of patients after IT with gemcitabine/cisplatin and the PD‑1 inhibitor tislelizumab (three cycles), a rate almost twice as high as with gemcitabine/cisplatin alone (NCT05211232). Intensification of dRCT in NPC using EGFR and VEGF inhibitors appears promising (NCT04447326). Abstracts on salivary gland and nasal and sinus cancers emphasize the importance of targeted therapies. In anaplastic thyroid carcinoma, the combination of a PD‑1 inhibitor and a CTLA4 inhibitor showed a 50% response.

P1, N=74, Recruiting, Peking University

P1, N=122, Terminated, Novartis Pharmaceuticals | Trial completion date: Jan 2025 --> Sep 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Sep 2024; The decision of early termination was made due to business reasons, and was not based on any safety concerns for any of the treatment combinations.

P2, N=34, Recruiting, Wuhan Union Hospital, China

P1/2, N=320, Not yet recruiting, LaNova Medicines Limited

P=N/A, N=74, Not yet recruiting, Southwest Hospital, China

P4, N=180, Not yet recruiting, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center

P2, N=33, Not yet recruiting, Affiliated Hospital of Guangdong Medical University; Affiliated Hospital of Guangdong Medical University

P2, N=36, Not yet recruiting, West China Hospital, Sichuan University; West China Hospital, Sichuan University

P2, N=46, Not yet recruiting, Anhui Provincial Cancer Hospital; Anhui Provincial Cancer Hospital

P1, N=26, Not yet recruiting, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital); The Tenth Affiliated Hospital, Southern Medical University(Do

P1, N=92, Not yet recruiting, Jilin Cancer Hospital; Jilin Cancer Hospital

P3, N=180, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting

P3, N=370, Active, not recruiting, BeiGene | Trial completion date: Dec 2024 --> Jun 2026 | Trial primary completion date: Nov 2024 --> Jun 2025

P2, N=20, Enrolling by invitation, The First Affiliated Hospital of Xiamen University

P2, N=24, Not yet recruiting, Sun Yat-sen University

P2, N=82, Not yet recruiting, Shanghai Zhongshan Hospital | Trial completion date: Jul 2028 --> Dec 2028 | Initiation date: Jul 2024 --> Nov 2024 | Trial primary completion date: Jul 2027 --> Dec 2027

This case demonstrates the feasibility of safely achieving stable cancer control in a kidney transplant patient with mUC without encountering graft rejection by using single-agent anti-PD-1 treatment.

P1/2, N=344, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Mar 2026 | Trial primary completion date: Jan 2027 --> Mar 2026

P2, N=121, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting

P2, N=30, Recruiting, Anhui Provincial Hospital

P1/2, N=53, Completed, BeiGene | Active, not recruiting --> Completed | Trial completion date: Feb 2025 --> Aug 2024

P2, N=32, Not yet recruiting, Shanghai Chest Hospital

P1/2, N=490, Recruiting, Nanjing Leads Biolabs Co.,Ltd | Trial completion date: Jun 2025 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Oct 2025

DKN-01 can be safely combined with frontline fluoropyrimidine/oxaliplatin and tislelizumab and demonstrates encouraging activity independent of PD-L1 expression levels. A randomized phase II trial is ongoing (ClinicalTrials.gov identifier: NCT04363801).

P2, N=35, Not yet recruiting, The Affiliated Hospital of Qingdao University

P2, N=67, Recruiting, Hebei Medical University Fourth Hospital

P2, N=46, Completed, BeiGene | Active, not recruiting --> Completed

P=N/A, N=20, Recruiting, Fujian Provincial Hospital | Not yet recruiting --> Recruiting

P1, N=62, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | N=42 --> 62

P3, N=649, Completed, BeiGene | Active, not recruiting --> Completed

However, it also represents the first reported case of fatal hemoptysis with this specific treatment regimen. This finding emphasizes the need for increased awareness of this potential complication, especially in patients with centrally located PSC treated with anti-angiogenic agents like anlotinib.

12 patients received Nivolumab plus Ipilimumab regimen and 8 patients received PD-1 blockades (2 patients were Pembrolizumab, 2 patients were Sintilimab, 4 patients were Tislelizumab) monotherapy. Furthermore, the study suggested that dual immunotherapy could potentially increase the immunotherapy cycle and contribute to a superior pCR rate. However, the conclusion emphasized the need for further prospective clinical trials to validate these results.

Tumor progression occurred after six cycles of Tislelizumab combined with chemotherapy (gemcitabine and cisplatin) followed by five cycles of Tislelizumab monotherapy. The prognosis of advanced urothelial carcinoma with trophoblastic differentiation is unfavorable, and the available therapeutic options are limited. Combining Tislelizumab with Disitamab vedotin presents a promising anti-tumor strategy that warrants further investigation.

In this paper, we reported a case of immune checkpoint inhibitor-associated severe pneumonia, referred to the relevant guidelines, introduced its clinical features, laboratory and imaging findings, difficulties encountered in the diagnosis and treatment process, briefly analyzed the causes, and reviewed the possibility of immune-related pneumonia should be considered when respiratory symptoms occurred in patients receiving immunotherapy; the increased ratio of blood neutrophil count to lymphocyte count, and the increased ratio of eosinophil count to lymphocyte count could be used as indicators to indicate immune-related adverse reactions in patients; bronchoalveolar lavage fluid examination and bronchoscopy and lung biopsy were helpful for the diagnosis; when immune checkpoint inhibitor-associated severe pneumonia occurred, in addition to symptomatic and sup-portive treatment, adequate glucocorticoid-based immunosuppressive therapy should be given in time, and combined with cytokines monoclonal antibodies and other biological agents, immunoglobulin co-therapy, but the current indications for the use of biological agents were not fully clear, and the use of high-dose immunosuppressive drugs might cause the risk of severe infection. Therefore, according to the relevant literature and the findings in the process of clinical diagnosis and treatment, this paper proposed that the serum levels of IL-6, TNF-α, CRP and other inflammatory mediators in patients may be used as a quantitative indication to initiate biological agent therapy and accumulate experience for better solving similar problems in the future.

In our research, node-sparing modified radiotherapy combined with immunotherapy probably increased the responsiveness of immunotherapy for MSS/pMMR rectal cancer patients, reduced the occurrence of postoperative rectal fibrosis, and improved survival and quality of life. This is the first clinical trial to utilize a node-sparing radiation strategy combined with chemotherapy and PD-1 blockade in the neoadjuvant treatment of rectal cancer, which may result in a breakthrough in the treatment of MSS/pMMR rectal cancer.

P=N/A, N=84, Recruiting, First Hospital of China Medical University

P2, N=342, Active, not recruiting, BeiGene | Phase classification: P1 --> P2

P2, N=40, Not yet recruiting, Fujian Medical University Union Hospital

P=N/A, N=97, Active, not recruiting, First Hospital of China Medical University

P=N/A, N=228, Recruiting, First Hospital of China Medical University